UPSTREAM MG
UPSTREAM MG Clinical Study · Phase 3

A Phase 3 study for adults living with generalized myasthenia gravis.

There is no cost to take part in the UPSTREAM MG study. Study-related care and investigational medication are provided at no cost and overseen by a specialized medical team. Compensation for travel may be available.

Please discuss study participation with your treating doctor.

I'm interested Call 1-877-513-1460

Registering is not a commitment to join the study.

About the study

What is the UPSTREAM MG study?

UPSTREAM MG is a global clinical study. It is testing an called in adults who live with () with or .1

Telitacicept is an investigational medicine being studied in adults with generalized myasthenia gravis. This medicine inhibits signaling molecules involved in the production of autoantibodies. This study is being done to learn more about how safe and effective telitacicept may be for adults living with gMG.1

NOTE: If your initial antibody test is negative, you may be retested using a more sensitive, less routine test.

  • Phase

    0

    clinical study of telitacicept for generalized myasthenia gravis (gMG).

  • Adults

    0 +

    years of age may be considered.

  • Initial

    0 -week

    randomized treatment period with telitacicept or placebo.

  • Extension

    0 +-week

    open-label extension—eligible participants receive telitacicept. No placebo in this period.

  • Total

    0 + weeks

    of participation, depending on how long you remain in the study.

  • Required

    0

    vaccinations are required to participate in the trial.

Eligibility

Who may be able to join?

Adults 18 years and older who have been diagnosed with gMG with AChr-Ab or MuSK-Ab may be considered. Final eligibility is determined by the study team during . If your initial antibody test is negative, you may be retested using a more sensitive, less routine test.1

You may be able to join if you 1:

  • Are 18 years of age or older
  • Have been diagnosed with generalized myasthenia gravis (gMG)
  • Have symptoms of muscle weakness that match the study's requirements
  • Meet other medical criteria that the study doctor will review with you, such as certain MG assessment scores and antibody test results

You may not be eligible if you 1:

  • Have certain other autoimmune diseases
  • Have certain active or chronic infections, or a medical history that could make study participation unsafe
  • Have had certain cancers or serious heart, liver, kidney, lung, or blood conditions that do not meet the study requirements
  • Have had specific thymus-related conditions or procedures that are excluded by the study protocol
  • Do not meet the study's required MG assessment scores or antibody testing criteria

Final eligibility is determined by the study team during screening. Each clinical study has detailed rules, called inclusion and exclusion criteria, to help keep participants safe and to make study results clear.

Participation timeline

How long does participation last?

Participation may exceed 84 weeks—about 4 weeks of screening, 24 weeks of first treatment, at least 48 weeks of open-label extension, and about 8 weeks of follow-up. An additional open-label extension may continue for a variable length of time depending on approval.1

A group of older adults laughing together in warm sunlight — the kind of community feeling a study journey can include.

Our study drug will be administered as weekly injections, some of which may be self-injected (or given by a caregiver) at home between study visits.1

  1. 01

    4 weeks

    Screening

    The study team reviews medical history, performs exams and tests, and confirms whether all eligibility criteria are met.

  2. 02

    24 weeks

    First treatment period

    Participants who qualify are randomly assigned to receive either telitacicept or placebo. Neither the participants nor the study team know which treatment is assigned during this part of the study.

  3. 03

    at least 48 weeks

    Extension treatment period

    Participants who complete the first treatment period and continue in the study can enter an extension period where everyone receives telitacicept. No placebo is given in this extension period.

  4. 04

    ongoing

    Open-label extension

    After 48 weeks, eligible participants may continue to receive telitacicept until the medicine is approved for gMG in their country, development is stopped, they choose to stop with their doctor, or the study ends.

  5. 05

    ~8 weeks

    Follow-up

    After study treatment ends, participants may have additional visits or contacts so the study team can check their health and collect final study information.

Total time in the study can exceed 84 weeks, depending on how long you continue. The exact visit schedule will be explained by the study team. In general, you can expect regular visits during screening and the treatment periods, along with possible home injections between some on-site visits.

Locations

Where are the study sites?

The UPSTREAM MG study has 21 sites across 12 US states. Final site selection is confirmed by the study team.

Hover over a dot to see the state, or enter your ZIP code to jump to the nearest listed site on ClinicalTrials.gov (NCT06456580).

12

States

21

Sites

If you don't see a site near you, email study@vorbio.com

Study reach21 sites · 12 states

Each red pin marks a listed study site. Highlighted states host the UPSTREAM MG study.

UPSTREAM MG is a global study with additional sites in South America, Europe, Australia, and Japan.

Study site location and details are subject to change.

All study states

Listed sites by state

Source: ClinicalTrials.gov (NCT06456580). Study locations may be updated.

Arizona

1
  • Scottsdale

California

3
  • Los Angeles
  • Orange
  • San Francisco

Florida

4
  • Boca Raton
  • Miami
  • Port Charlotte
  • Tampa

Georgia

1
  • Augusta

Kansas

1
  • Kansas City

Kentucky

2
  • Lexington
  • Louisville

Massachusetts

1
  • Foxborough

Michigan

2
  • East Lansing
  • Grand Rapids

New York

2
  • New York
  • The Bronx

Ohio

1
  • Cincinnati

Texas

2
  • Dallas
  • Houston

Wisconsin

1
  • Greenfield

If you don't see a site near you, email study@vorbio.com
Sign up

Participation is voluntary. Your information is only used to contact you about the UPSTREAM MG study.

Ready to take the next step?

Registering takes just a minute and is not a commitment to join the study. A member of the study team may contact you to share more information and answer questions.

Your information will be kept confidential.
I am filling this out for
*Required fields.

By providing your phone number, you agree that the study team may contact you by phone or text message regarding the UPSTREAM MG study. Message and data rates may apply; message frequency varies. Reply STOP to opt out or HELP for help.

1-877-513-1460

Registering takes about a minute and is not a commitment to join the study. Participation is entirely voluntary. A member of the study team may contact you with more information, and—if a participating study site is available in your area—to help determine whether you may be eligible. If no site is currently open near you, we may reach out in the future about new opportunities that could be a good fit.

The information you provide will be processed in accordance with our Privacy Policy , which describes how we collect, use, and share your information with the study sponsor (Vor Biopharma) and its research partners for the purpose of clinical trial recruitment. By submitting this form, you consent to the use of your information as described in the Privacy Policy. To ask questions, update your information, or withdraw your consent, contact us at study@vorbio.com .

Frequently asked

Questions people commonly ask.

A few of the most common questions. See the full library if you'd like to go deeper before you register.

01 Who may be able to join?
You may be able to join if you are 18 years of age or older, have been diagnosed with generalized myasthenia gravis, and meet the study's medical requirements.1 Final eligibility is determined by the study team during screening.
02 Will everyone receive the study drug?
Yes, but not necessarily at first. During the first treatment period, participants who qualify are randomly assigned to receive either the study drug (telitacicept) or a placebo for 24 weeks. The placebo looks the same but does not contain active ingredients. In the extension period, participants who continue the study receive telitacicept. There is no placebo in the extension phase.1
03 How long could participation last?
Participation includes about 4 weeks of screening, a 24-week first treatment period, an extension treatment period of at least 48 weeks, an open-label extension that may continue longer, and an 8-week follow-up. Total time in the study can exceed 84 weeks, depending on how long you continue.1
04 Is taking part voluntary?
While you can leave the study for any reason or at any time, deciding not to take part will not impact your current or future medical care. Taking part in the UPSTREAM MG study is completely voluntary.
See all frequently asked questions

Reference

Medically reviewed · May 2026

  1. A study of telitacicept for the treatment of generalized myasthenia gravis (UPSTREAM MG). ClinicalTrials.gov identifier: NCT06456580. Updated May 7, 2026. Accessed May 14, 2026. https://clinicaltrials.gov/study/NCT06456580
I'm interested